Search Results
Nov 10, 2025, 08:47 ET Gigli Glows Up: The THC Beverage Brand Lighting Up Mainstream Shelves
Strawberry Spritz, and Cherry Limeade — serves up bold taste with real juice, low calories, and all-natural, ingredients. Available in 2 mg, 5 mg, and 10 mg THC options, Gigli offers a feel-good glow for every occasion. The brand's focus on quality and craft hasn't gone
More news about: Gigli
Nov 10, 2025, 08:46 ET Novo Nordisk's Wegovy® (semaglutide 2.4 mg) was associated with liver health-related benefits not solely based on weight loss in adult patients with MASH with liver scarring, according to a new post hoc analysis
(semaglutide 2.4 mg) injection was associated with resolution in liver injury, while improvements in liver scarring trended to favor semaglutide 2.4 mg1 An additional secondary analysis found that semaglutide 2.4 mg, when compared
More news about: NOVO NORDISK INC.
Nov 10, 2025, 08:45 ET Novo Nordisk's Wegovy® (semaglutide 2.4 mg) was associated with liver health-related benefits not solely based on weight loss in adult patients with MASH with liver scarring, according to a new post hoc analysis
(semaglutide 2.4 mg) injection was associated with resolution in liver injury, while improvements in liver scarring trended to favor semaglutide 2.4 mg1 An additional secondary analysis found that semaglutide 2.4 mg, when compared
More news about: NOVO NORDISK INC.
Nov 10, 2025, 08:00 ET Acurx Announces Publication in the Nature Communications Scientific Journal Documenting its Unique Targeting of DNA pol IIIC Gram-positive Priority Pathogens
In the Phase 2b trial segment, 32 patients with CDI were enrolled and randomized in a 1:1 ratio to either ibezapolstat 450 mg every 12 hours or vancomycin 125 mg orally every 6 hours, in each case, for 10 days and followed for 28 ± 2 days following the end of treatment for recurrence of CDI.
More news about: Acurx Pharmaceuticals, Inc.
Nov 10, 2025, 08:00 ET Servier's Clinical and Real-World Data at 2025 SNO Congress Showcase Leadership in IDH-Mutant Glioma
INFORMATION What is VORANIGO? VORANIGO (40 mg tablets) is a prescription medicine used to treat adults and children 12 years of age and older with certain types of brain tumors called astrocytoma
More news about: Servier Pharmaceuticals
Nov 10, 2025, 07:15 ET Par Health Reports Third Quarter 2025 Financial Results and Provides Business Update
$80.1 million in the third quarter of 2024, a decrease of 24.5%. The Company's launch of ADRENALIN® Ready-to-Use premixed IV bags in 2mg, 5mg and 10mg concentrations partially offset the impact of competitive pressures on price and volume of VASOSTRICT® and ADRENALIN vials.
More news about: Par Health
Nov 10, 2025, 07:00 ET CalciMedica Presents Data from Preclinical Study of Auxora™ in an Animal Model of AKI at ASN Kidney Week 2025
In the study, rat models of ischemia/reperfusion (I/R)-induced acute kidney injury (AKI) were treated with either Auxora™ (16 mg/kg, administered intravenously over 4 hours) or placebo at 6, 24, and 48 hours following I/R. GFR was reassessed at 72 hours to evaluate the effects of
More news about: CalciMedica, Inc.
Nov 10, 2025, 02:44 ET Camurus reports positive topline results for CAM2056, semaglutide monthly depot
administered for five months according to the prescribing information (Wegovy®)1. The highest CAM2056 initiation dose was 5 mg and the highest monthly dose was 15 mg. Camurus plans to start a Phase 2b trial of CAM2056 in 2026, featuring longer treatment duration and elevated doses.
More news about: Camurus AB
Nov 10, 2025, 02:41 ET Camurus reports positive topline results for CAM2056, semaglutide monthly depot
administered for five months according to the prescribing information (Wegovy®)1. The highest CAM2056 initiation dose was 5 mg and the highest monthly dose was 15 mg. Camurus plans to start a Phase 2b trial of CAM2056 in 2026, featuring longer treatment duration and elevated doses.
More news about: Camurus AB
Nov 09, 2025, 23:00 ET Rona Therapeutics Presents Phase 1 Data for RN0361, a Long-Acting APOC3-Targeting siRNA, at the American Heart Association 2025 Scientific Sessions
DePaoli, MD, CMO. The randomized, placebo-controlled Single Ascending Dose (SAD) study in volunteers with baseline TG >80 mg/dl showed favorable tolerability, no serious adverse events, with mild, self-limited injection-site reactions (ISRs) and transient ALT and AST elevations
More news about: Rona Therapeutics
Nov 09, 2025, 23:00 ET Rona Therapeutics Presents Phase 1 Data for RN0361, a Long-Acting APOC3-Targeting siRNA, at the American Heart Association 2025 Scientific Sessions
DePaoli, MD, CMO. The randomized, placebo-controlled Single Ascending Dose (SAD) study in volunteers with baseline TG >80 mg/dl showed favorable tolerability, no serious adverse events, with mild, self-limited injection-site reactions (ISRs) and transient ALT and AST elevations
More news about: Rona Therapeutics
Nov 09, 2025, 20:55 ET Kelun-Biotech Presented TROP2 ADC Sacituzumab Tirumotecan Results From Multiple Clinical Studies at the 2025 CCHIO Congress
sac-TMT 4 mg/kg group and 44 patients to the sac-TMT 5 mg/kg group. At data cutoff (May 21, 2025), median (range) follow-up was 11.7 months in the 4 mg/kg group and 21.8 months in the 5 mg/kg group. Confirmed objective response rate (ORR) was 30.7% and 34.1% in the 4 mg/kg and 5
More news about: Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
Nov 09, 2025, 03:00 ET Première thérapie mondiale d'édition génique ciblant l'APOC3 pour le traitement de l'hyperlipidémie
causée par des mutations bialléliques du gène de la lipoprotéine lipase (LPL) ou d'autres gènes régulateurs clés, avec des TG à jeun ≥ 10 mmol/L (885 mg/dL) et une prévalence mondiale de 1 cas sur 100 000-1 000 000 personnes. Le syndrome de chylomicronémie multifactorielle est le résultat d'une interaction
More news about: CorrectSequence Therapeutics
Nov 08, 2025, 10:40 ET Clinically meaningful pivotal study results for olezarsen in sHTG presented as a late breaker at AHA Scientific Sessions
the olezarsen group (pooled 50 mg and 80 mg dose groups). Olezarsen demonstrated a favourable safety and tolerability profile in the CORE and CORE2 studies. Adverse events were balanced across treatment arms (75% olezarsen 50 mg; 76% olezarsen 80 mg; 75% placebo). Serious adverse
More news about: Swedish Orphan Biovitrum AB
Nov 08, 2025, 10:15 ET AMGEN'S REPATHA® CUTS RISK OF FIRST MAJOR ADVERSE CARDIOVASCULAR EVENTS BY 25% IN LANDMARK PHASE 3 VESALIUS-CV TRIAL
attack or stroke, an LDL-C ≥ 90 mg/dL, or non-high-density lipoprotein cholesterol (non-HDL-C) ≥ 120 mg/dL, or apolipoprotein B ≥ 80 mg/dL; and treated with highest tolerated dose of statin and/or ezetimibe. The median baseline LDL-C was 122 mg/dL (IQR, 104-149 mg/dL) on local lab testing. Participants
More news about: Amgen
Nov 08, 2025, 08:30 ET AusperBio Announces Late-Breaking 48-Week Phase II Data of AHB-137 in Chronic Hepatitis B at AASLD 2025
including complete response (HBsAg < 0.05 IU/mL and HBV DNA < LLOQ) and partial response (HBsAg < 10 IU/mL and HBV DNA < LLOQ). The 300 mg, 24-week regimen showed the highest response rates, with efficacy consistent across baseline HBsAg strata. AHB-137 was well tolerated, and no new safety
More news about: AusperBio Therapeutics Inc.
Nov 08, 2025, 01:42 ET DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Jasper
2025, Jasper issued a press release reporting updated data from the BEACON Study. The press release stated that "[r]esults from the 240mg Q8W and the 240mg followed by 180mg Q8W dose cohorts appear to be confounded by an issue with one drug product lot used in those cohorts, with 10 of the 13 patients dosed
More news about: Faruqi & Faruqi, LLP
Nov 08, 2025, 01:33 ET DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of aTyr Pharma
corticosteroid (OCS) dose at week 48, with the OCS dose reducing by an average of 2.79mg for 5.0 mg/kg efzofitimod compared to 3.52 mg for placebo. Complete steroid withdrawal was achieved for 52.6% of patients treated with 5.0 mg/kg efzofitimod versus 40.2% on placebo. After aTyr Pharma
More news about: Faruqi & Faruqi, LLP
Nov 07, 2025, 19:29 ET U.S. FDA approves KYGEVVI™ (doxecitine and doxribtimine), the first and only treatment for adults and children living with thymidine kinase 2 deficiency (TK2d)
years).1 The median duration of treatment was 4 years (range: 1 day to 12 years) and the median dose received was 762 mg/kg/day (range: 260 to 800 mg/kg/day).1 The most common adverse reactions (incidence ≥5%) are diarrhea, abdominal pain (including abdominal pain
More news about: UCB
Nov 07, 2025, 14:18 ET CANDICE SWANEPOEL, EL ICÓNICO ÁNGEL VICTORIA'S SECRET® LLEGÓ A CIUDAD DE MÉXICO
Geraldine Galván, Paola Wise, Mónica Murillo, Lynn Vizcarra, Mónica Saldivar, Paris Danielle, Frida Sahagún, Maria Riestra, Annesy Lozano, Becky Mg, Diana Paulina, Valeria Rincón, Elena Escobar, Andrea Rodríguez, Cami Corona, Pamela Mcbeath, Natalya Galilea, America Planter and Marietta Rojas.
More news about: Victoria's Secret
Nov 07, 2025, 09:00 ET HanchorBio Presents Two Late-Breaking Abstracts at the Society for Immunotherapy of Cancer 2025 Demonstrating Best-in-Class Potential of HCB101 in Advanced Cancers
ongoing Phase 1a dose-escalation, no dose-limiting toxicities (DLTs) have been observed at doses up to 24 mg/kg. CD47 receptor occupancy ≥99% achieved at doses ≥5 mg/kg, with dose-proportional pharmacokinetics. Confirmed partial responses seen in head
More news about: HanchorBio Inc.
Nov 07, 2025, 09:00 ET CREATE Medicines Announces Positive First-in-Human Results for MT-302
were no events of grade 3 or higher CRS. Maximum tolerated dose: 0.10 mg/kg without steroid premedication. One Grade 4 ICANS event was observed at the highest dose tested (0.15 mg/kg). Pharmacokinetics: terminal half-life of pegylated and ionizable lipids
More news about: CREATE Medicines, Inc.
Nov 07, 2025, 08:52 ET Weltweit erste, auf APOC3 abzielende Gen-Editing-Therapie zur Behandlung von Hyperlipidämie
Mutationen im Lipoproteinlipase (LPL)-Gen oder anderen wichtigen regulatorischen Genen verursacht wird, mit einem Nüchtern-TG-Wert von ≥10 mmol/L (885 mg/dL) und einer globalen Prävalenz von 1 zu 100.000–1.000.000. MCS ist das Ergebnis eines komplexen Zusammenspiels von genetischen, lebensstilbedingten
More news about: CorrectSequence Therapeutics
Nov 07, 2025, 08:31 ET MetaVia Presents Positive New Phase 2a Data on Vanoglipel (DA-1241) in Patients with Presumed MASH at the AASLD The Liver Meeting® 2025
MASH and qualifying baseline alanine transaminase (ALT) and imaging analyses were randomized to receive placebo, vanoglipel 50 mg, vanoglipel 100 mg alone, or vanoglipel 100 mg with a DPP4 inhibitor once daily for 16 weeks in a 2:1:2:2 ratio. "The encouraging additional Phase 2a
More news about: MetaVia Inc.
Nov 07, 2025, 08:30 ET 騰盛博藥宣佈在《自然-醫學》發表ENSURE II期研究結果
IU/L）被分類為BRII-179抗-HBs應答者或無應答者，隨後在ENSURE研究中接受48周的elebsiran（100 mg Q4W）聯合每週PEG-IFNα治療。 該論文的關鍵結果包括： 隊列1-3：在治療結束後24周，在隊列2（elebsiran 200mg + PEG-IFNα）的19名參與者中4例（21.1%）實現了HBsAg清除；在隊列3（elebsiran 100 mg + PEG-IFNα）的18 名參與者中6例（33.3%）實現了HBsAg清除。相比之下，隊列1（PEG-IFNα單藥）18名參與者中僅有1例（5.6%）實現了HBsAg清除。
More news about: 騰盛博藥生物科技有限公司